Related Experiment Video
Updated: Aug 9, 2026
11:36
Induction of Drug-Induced, Autoimmune Hepatitis in BALB/c Mice for the Study of Its Pathogenic Mechanisms
Published on: May 29, 2020
Budesonide induces complete remission in autoimmune hepatitis
Antal Csepregi1, Christoph Röcken, Gerhard Treiber
1Department of Gastroenterology, Otto-von-Guericke University, Leipziger Str 44, D-39120 Magdeburg, Germany. csepregi.antal@medizin.uni-magdeburg.de
World Journal of Gastroenterology
|March 23, 2006
Summary
Budesonide (BUD) effectively induces remission in most autoimmune hepatitis (AIH) patients. However, budesonide treatment failure and side effects were primarily noted in patients with liver cirrhosis.
Area of Science:
- Hepatology
- Immunology
- Gastroenterology
Background:
- Autoimmune hepatitis (AIH) is typically managed with prednisone and azathioprine.
- Complete histological remission rates with standard therapy are suboptimal, affecting approximately 65% of patients.
- Budesonide (BUD) has emerged as a potential alternative treatment for AIH.
Purpose of the Study:
- To evaluate the efficacy and safety of budesonide (BUD) in patients diagnosed with autoimmune hepatitis (AIH).
Main Methods:
- Eighteen patients with AIH received budesonide (BUD) at 3 mg thrice daily for a minimum of 24 weeks.
- The study included patients with co-existing primary biliary cirrhosis or primary sclerosing cholangitis, and some with advanced liver fibrosis or cirrhosis.
- Clinical, biochemical, and histological assessments were performed to monitor treatment response and safety.
Main Results:
- A high rate of clinical and biochemical remission (83%) was observed in patients treated with budesonide (BUD).
- First-line budesonide therapy led to remission in 70% of patients, while second-line therapy resulted in long-term remission for all patients.
- Histological remission was achieved in three patients, and clinically significant side effects were predominantly seen in patients with liver cirrhosis.
Conclusions:
- Budesonide (BUD) demonstrates significant efficacy in inducing remission for the majority of autoimmune hepatitis (AIH) patients.
- Treatment failure and adverse events associated with budesonide were mainly concentrated in patients presenting with liver cirrhosis.
Related Concept Videos
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
01:29Drugs for Treatment of Ulcerative Colitis in IBD
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.
01:17Chronic Bowel Disorders: Introduction
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...